Literature DB >> 10682123

Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation.

P A Cane1, D Mutimer, D Ratcliffe, P Cook, G Beards, E Elias, D Pillay.   

Abstract

This report describes nucleotide sequence analysis of part of the polymerase gene of hepatitis B virus (HBV) during the development of lamivudine-resistant HBV in five patients who received lamivudine treatment in conjunction with liver transplantation. Samples from patients were analysed before, during and after drug treatment in conjunction with serum HBV quantification by PCR. Lamivudine resistance was found to be associated with L526M and M550V changes in two patients and M550I change in three patients. Other changes associated with lamivudine resistance in some patients were V509I, A546V, S565A and A568T. The effects on HBV surface antigen are also described. Some patients were subsequently treated with famciclovir and/or ganciclovir with variable outcomes. In two out of three patients who stopped lamivudine treatment, reversion (partial or complete) to wild-type virus was observed after about 5 months. In contrast, a complex mixture of mutant viruses emerged in a third patient who stopped lamivudine treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10682123

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  10 in total

1.  Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus.

Authors:  N J Burroughs; D Pillay; D Mutimer
Journal:  Proc Biol Sci       Date:  1999-12-07       Impact factor: 5.349

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  Dynamics of hepatitis B virus resistance to lamivudine.

Authors:  Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; Patrice Nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 4.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus.

Authors:  P A Cane; P Cook; D Ratcliffe; D Mutimer; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 6.  Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.

Authors:  K Deres; H Rübsamen-Waigmann
Journal:  Infection       Date:  1999       Impact factor: 3.553

7.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

Review 8.  Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

Authors:  Jean-Michel Pawlotsky; Geoffrey Dusheiko; Angelos Hatzakis; Daryl Lau; George Lau; T Jake Liang; Stephen Locarnini; Paul Martin; Douglas D Richman; Fabien Zoulim
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

9.  Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B.

Authors:  Do Young Kim; Hye Young Chang; Sun Min Lim; Seung Up Kim; Jun Yong Park; Ja Kyung Kim; Kwan Sik Lee; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  Gut Liver       Date:  2013-04-09       Impact factor: 4.519

Review 10.  Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy.

Authors:  Eriko Ohsaki; Yadarat Suwanmanee; Keiji Ueda
Journal:  Viruses       Date:  2021-08-26       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.